ArticleInternational urology and nephrology2026
Sustained tenascin-C activation drives AKI-to-CKD progression via the Wnt/β-catenin pathway.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Acute kidney injury (AKI) serves as an independent risk factor contributing to the progression toward chronic kidney disease (CKD). Tenascin-C (TNC), an extracellular matrix glycoprotein, has been implicated in renal protection following AKI. However, its involvement in the transition from AKI to CKD remains unclear. This study investigates the role of TNC in murine models subjected to varying severities of ischemia/reperfusion injury (IRI), including mild IRI (20 min of ischemia) and severe IRI (30 min of ischemia). Mild IRI induced a transient renal dysfunction accompanied by transient TNC activation, followed by apparent recovery of renal structure and function within the period. In contrast, severe IRI triggered sustained and excessive TNC expression, coinciding with the onset of renal fibrosis. To assess the contribution of persistent TNC expression in promoting AKI-to-CKD progression, TNC was either overexpressed or silenced using shRNA plasmids. In vivo, TNC overexpression five days post-IRI activated β-catenin signaling and accelerated CKD development. Conversely, TNC knockdown suppressed β-catenin activation and mitigated disease progression. In vitro, TNC was found to interact with Wnt ligands via epidermal growth factor receptor (EGFR), as demonstrated by co-immunoprecipitation assays, thereby amplifying Wnt-induced β-catenin activation. These findings suggest that sustained, rather than transient, TNC activation may play a critical role in facilitating the AKI-to-CKD transition by modulating Wnt/β-catenin signaling through EGFR.
Indexed as
Identifiers
41790418What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.